Here, we reported a case of heterochronous double primary malignancy of breast cancer combined with ALK-positive advanced LCNEC, in which the patient experienced a beneficial response to ALK-TKI therapy following the failure of postoperative adjuvant therapy. The gene discussed is ALK; the disease is large cell neuroendocrine carcinoma.